Prospective, randomized, controlled study to evaluate the direct effect of specific movement therapy with professional supervision by various Inteventionen on the Fatigue Syndrome

Prospective, randomized, controlled study to evaluate the direct effect of specific movement therapy with professional supervision by various Inteventionen on the Fatigue Syndrome - FatiGo-Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00007798

Enrollment

125

Registered

2015-05-05

Start date

2019-11-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue F48

Interventions

Group 1: Control group (there will be no training, but patients fill about 4 week the questionnaires and can then work on the OTT) Group 2: strength group (moderate intensity of 50-60%, the training t

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: Patients with a history of malignancy (all entities) Patients in the follow-up Fatigue VAS >3 completed chemotherapy Age> = 18 years written and valid informed consent

Exclusion criteria

Exclusion criteria: • VAS 69 years • Hormone therapy • Palliative patients or with advanced cancer • Ongoing chemotherapy, ongoing radiation • Conditions that cause fatigue • Medications that can affect severe fatigue • Activity level> 1 hour of exercise per week • All illness situations that do not allow sporting activity, in particular: o Clinically manifest heart failure (NYHA III-IV) o Partial or global respiratory failure o Permanent thrombocytopenia <10,000 / µl, e.g. refractory autoimmune thrombocytopenias o Congenital or acquired thrombocytopathies or coagulation disorders o Symptomatic CHD (exercise ECG and cardiac ultrasound recommended if necessary) o Severe refractory hypertension o Non-adjustable COPD o Uncontrolled cerebral convulsions o Severe anemia (requiring a transfusion) o metastases • Medical or mental health condition that, in the opinion of the investigator, does not allow the patient to take part in the study or to provide a legally binding consent form • Unwillingness to save and pass on personal illness data within the scope of the protocol • Participation in another sports study

Design outcomes

Primary

Measure	Time frame
Evaluation of the immediate effectiveness of targeted exercise therapy with professional supervision through various interventions on the fatigue syndrome (MFI20).	—

Secondary

Measure	Time frame
1. What intervention group and what intensity has the best effect on the Fatigue Syndrome? 2. What blood parameters play a role in fatigue? 3. Development of a training standard therapy Assessments: MFI20 = Fatigue VAS = Fatigue HADS = anxiety / depression h1RM = force Spiroergometry = endurance Freiburg Questionnaire / movisens = physical activity	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026